Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The present study aimed to investigate the impact of hydrogen (H) on chronic intermittent hypoxia (CIH)-induced cardiac hypertrophy in mice by modulating iron metabolism. C57BL/6N mice were randomly allocated into four groups: control (Con), CIH, CIH + H, and H. The mice were exposed to CIH (21-5% FiO, 3 min/cycle, 8 h/d), and received inhalation of a hydrogen-oxygen mixture (2 h/d) for 5 weeks. Cardiac and mitochondrial function, levels of reactive oxygen species (ROS), and iron levels were evaluated. The H9C2 cell line was subjected to intermittent hypoxia (IH) and treated with H. Firstly, we found H had a notable impact on cardiac hypertrophy, ameliorated pathological alterations and mitochondrial morphology induced by CIH ( < 0.05). Secondly, H exhibited a suppressive effect on oxidative injury by decreasing levels of inducible nitric oxide synthase (i-NOS) ( < 0.05) and 4-hydroxynonenal (4-HNE) ( < 0.01). Thirdly, H demonstrated a significant reduction in iron levels within myocardial cells through the upregulation of ferroportin 1 (FPN1) proteins ( < 0.01) and the downregulation of transferrin receptor 1 (TfR1), divalent metal transporter 1 with iron-responsive element (DMT1(+ire)), and ferritin light chain (FTL) mRNA or proteins ( < 0.05). Simultaneously, H exhibited the ability to decrease the levels of Fe and ROS in H9C2 cells exposed to IH ( < 0.05). Moreover, H mediated the expression of hepcidin, hypoxia-inducible factor-1α (HIF-1α) ( < 0.01), and iron regulatory proteins (IRPs), which might be involved in the regulation of iron-related transporter proteins. These results suggested that H may be beneficial in preventing cardiac hypertrophy, a condition associated with reduced iron toxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742465PMC
http://dx.doi.org/10.3390/cimb45120636DOI Listing

Publication Analysis

Top Keywords

cardiac hypertrophy
16
chronic intermittent
8
iron metabolism
8
intermittent hypoxia
8
iron levels
8
iron
6
cardiac
5
levels
5
hydrogen attenuates
4
attenuates chronic
4

Similar Publications

Introduction: Endurance athletes are expected to present a cardiac remodeling characterized by eccentric hypertrophy. Differentiation from underlying cardiomyopathy mimicking a similar cardiac remodeling may be challenging. Myocardial work indexes (MWI) have been shown to be useful in distinguishing between physiological adaption and pathological changes in the athletes' heart.

View Article and Find Full Text PDF

Selective therapeutic targeting of cardiomyocytes (CMs) and non-myocytes (NMs) within the heart is an active field of research. The success of those novel therapeutic strategies is linked to the ability to accurately assess uptake and gene delivery efficiencies in clinically relevant animal models. Nevertheless, quantification at the single cell level remains a significant challenge.

View Article and Find Full Text PDF

Complicated Lipomatous Hypertrophy of the Interatrial Septum: Multimodality Imaging in Diagnosis and Management.

JACC Case Rep

September 2025

Division of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Background: Lipomatous hypertrophy of the interatrial septum (LHIS) is a benign cardiac lesion characterized by excessive fat accumulation in the interatrial septum, often sparing the fossa ovalis. Although typically asymptomatic, severe cases may lead to hemodynamic compromise.

Cases Summary: We report 2 cases of exuberant symptomatic LHIS requiring surgical intervention.

View Article and Find Full Text PDF

Pathological cardiac hypertrophy, driven by mitochondrial dysfunction and maladaptive remodeling, remains a therapeutic challenge. This study explores the cardioprotective properties of tectorigenin (Tec) in the context of transverse aortic constriction (TAC)-induced hypertrophy, focusing on mitochondrial homeostasis. In animal models, administration of Tec improved survival rates, reduced cardiac dysfunction, and decreased hypertrophy and fibrosis in TAC mice, while preserving mitochondrial function.

View Article and Find Full Text PDF

Background: Primary healthcare centers (PHC) play a pivotal role in the first-line management of patients with diabetes and hypertension, major risk factors for heart failure (HF) development. Point-of-care cardiac ultrasound (POCUS), integrated as an extension of the physical examination, holds significant potential to enhance diagnostic accuracy and clinical management in this setting.

Objectives: Evaluate the impact of POCUS on clinical decision-making in patients with HF and at risk of developing HF in PHC and compare POCUS findings with clinical assessment alone, conventional echocardiography, and electrocardiogram results.

View Article and Find Full Text PDF